GSK’s vaccine for severe RSV shows 43.3% effectiveness in third year
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.
Drugs
Health
Pharma
Drugs
Health
Pharma
Sage Therapeutics halts trials of experimental drug to treat dementia
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.
Climate
Health
Pharma
Global glaciers suffer largest mass loss in 50 yrs, 2023 driest for rivers
Glaciers suffered the largest mass loss in 50 years as last year marked the driest for global rivers in 33 years, according to.
Drugs
Health
Pharma
US drug regulator clears Qnovia’s nicotine inhaler for clinical testing
HQ Team October 7, 2024: The US Food and Drug Administration (FDA)has cleared Qnovia Inc’s nicotine inhaler RespiRx for clinical trial. The US.
Climate
Health
Pharma
More than 200 land defenders died globally in 2023, Colombia deadliest
More than 200 people were murdered worldwide last year while trying to protect their lands and the environment from corporations, governments and non-state.
Drugs
Health
Pharma
Johnson & Johnson stops mid-stage trial of drug for dengue prevention
Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.
Drugs
Health
Pharma
Recordati buys Sanofi’s drug for autoimmune disease for $825 million
Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's.
Climate
Drugs
Pharma
Denmark’s Novo Nordisk to invest $158 million in Brazil insulin facility
Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments.
Drugs
Health
Pharma
EMA starts review of medicines to treat hair loss, prostate enlargement
The European Medicines Agency is reviewing two medicines meant to treat hair loss and prostate enlargement following concerns regarding suicidal ideation and behaviours.
Drugs
Health
Pharma
UK scientists receive funding to develop world’s first ovarian cancer vaccine
HQ Team October 4, 2024: Researchers at the University of Oxford have received £600,000 (€719,960) from Cancer Research UK to fund their project.